[Federal Register Volume 59, Number 210 (Tuesday, November 1, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-26971]
[[Page Unknown]]
[Federal Register: November 1, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health.
ACTION: Notice.
-----------------------------------------------------------------------
The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for U.S. companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by contacting Girish C.
Barua, Technology Licensing Specialist, Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804 (telephone 301/496-7735 ext. 263; fax
301/402-0220). A signed Confidential Disclosure Agreement will be
required to receive copies of the patent applications. Issued patents
may be obtained from the Commissioner of Patents, U.S. Patent and
Trademark Office, Washington, DC 20231.
Anti-HIV Compositions Containing Native And Recombinant Peptides
Fischinger, P.J., Wong-Staal, F., Gallo, R.C., Matthews, T.J. (NCI)
Filed 23 Feb 89
Serial No. 07/314,664
A kit containing substantially pure native and recombinant HIV
glycoproteins is valuable for testing anti-HIV vaccines or as
diagnostic aids for detecting HIV infection. Previously, it has been
difficult to obtain large, pure quantities of HIV proteins for use in
vaccines or diagnostic procedures. This kit contains deglycosylated
envelope proteins as well as recombinant fusion molecules containing
HIV and non-HIV amino acid sequences.
Production Of Complementary DNA Representing Hepatitis A Viral
Sequences By Recombinant DNA Methods And Uses Therefor
Ticehurst, J., Baltimore, D., Feinstone, S.M., Purcell, R.H.,
Racaniello, V.R., Baroudy, B.M., Emerson, S.U. (NIAID)
Filed 6 Nov 91
Serial No. 07/788,262 (CIP of 07/256,135, CON of 06/654,942, CIP of 06/
536,911)
A method for the production and use of single- and double-stranded
(ds) cDNA representing hepatitis A virus (HAV) sequences has been
discovered, including an infectious, full-length cDNA clone of wild-
type HAV. Large quantities of the novel HAV cDNA can be harvested at a
relatively low cost via insertion of the cDNA molecules into a
recombinant DNA vector and subsequent transformation in appropriate
cells; modification of bacteria by genetic engineering permits for the
production of ds HAV cDNA. The cDNA molecules hold substantial
diagnostic potential because they are highly specific and very
sensitive to HAV; they can also be used in the production of either HAV
antigen or antibodies to HAV antigen for possible vaccine development.
Currently, no vaccine is available for protection against HAV
infection.
Mammalian Guanine Nucleotide-Binding Protein With An ADP-
Ribosylation Factor Domain (ARD1)
Moss, J., Mishima, K., Nightingale, M.S., Tsuchiya, M. (NHLBI)
Filed 19 Apr 93
Serial No. 08/049,473
ADP-ribosylation factors (ARFs) constitute one family of the
-20-kDa guanine nucleotide-binding ras superfamily. ARFs
regulate secretory, endocytic, exocytic, and nuclear fusion events and
activate phospholipase D and cholera toxin. ARD1 is a 64-kDa protein
containing an ARF domain at its carboxy terminus. This invention
includes a cell line transfected with an expression vector containing
either rat or human ARD-1 DNA and an immunoassay kit for detecting ARD
proteins in samples.
Hepatitis A Vaccine
Nainan, O.V., Margolis, H.S., Robertson, B.H., Brinton, M.A., Ebert,
J.W. (CDC)
Filed 6 Jul 93
Serial No. 08/087,016 (FWC of 07/678,828)
A hepatitis A virus (HAV) was isolated from cynomolgus macaques,
and the capsid region of this new HAV was sequenced. It was found that
the amino acid sequence within the immunodominant site of the capsid
region is significantly different from that of other HAV isolates. This
new virus is suitable for preparing a whole virus vaccine for
preventing hepatitis A in animals and, potentially, in humans.
Hepatitis A Vaccine
Cohen, J.I., Purcell, R.H., Feinstone, S.M., Ticehurst, J.R. (NIAID)
Filed 13 Sep 93
Serial No. 08/120,646 (FWC of 07/789,640, CON of 07/462,916, CON of 07/
088,220)
A full-length DNA analog of the hepatitis A virus genome and RNA
transcripts of the DNA analog can be mutated to produce an infectious
hepatitis A virus suitable for a vaccine. Prior technologies have used
cell culture techniques, rather than recombinant DNA methods, in an
attempt to produce an acceptable hepatitis A entity. This new method
overcomes the difficulties associated with the random mutation
processes that occur with conventional methods.
Nucleic Acids Of A Novel Hantavirus And Reagents For Detection And
Prevention Of Infection
Nichol, S.T. (CDC)
Filed 7 Oct 93
Serial No. 08/133,591 (CIP of 08/084,724)
An outbreak of acute illness in the Four-Corners region of the
United States in the spring of 1993 has been associated with the Muerto
Canyon strain of hantavirus. The identification of specific nucleotide
sequence information for this virus will aid in the development of
diagnostic assays and vaccines.
Plasmids For Efficient Expression Of Synthetic Genes In E. Coli
Fields, H.A., Khudyakov, Y. (CDC)
Filed 25 Oct 93
Serial No. 08/141,917
This invention covers the development of a recombinant gene
encoding the hepatitis C nucleocapsid protein, which offers to
significantly improve the detection and diagnosis of this disease.
Hepatitis C virus (HCV) is a recently identified agent responsible for
most cases of post-transfusion non-A, non-B hepatitis worldwide. The N-
terminal region of the HCV polyprotein is processed into proteins C (a
nucleocapsid) and EI and E2/NS1 (envelope proteins). Previously, there
has been no acceptable immunoassay kit for detecting HIV infection
because growing the virus in bacteria has been difficult. Therefore,
there has been no large-scale source of HCV proteins from which to
stimulate the production of antibodies for immunoassays. This problem
has been addressed by cloning the sequence from HCV nucleocapsid
protein and inserting it into an expression vector with a Shine-
Dalgarno, which enhances expression of the protein encoded by the
nucleotide sequence. Thus, an E. coli can be used as a host for the
vector, and large amounts of protein are produced even when there is
low copy number of the vector.
Clones Encoding Mammalian ADP-Ribosylarginine Hydrolases
Moss, J., Stanley, S.J., Nightingale, M.S., Murtagh, J.J., Monaco, L.,
Takada, T. (NHLBI)
Serial No. 08/183,214 (DIV of 07/888,231)
ADP-ribosylation of arginine residues in proteins may be involved
in cell adhesion and is crucial for the action of cholera toxin and E.
coli heat-labile enterotoxin, agents involved in the pathogenesis of
cholera and traveller's diarrhoea, respectively. ADP-ribosylation is
reversed by ADP-ribosylarginine hydrolases, which cleave the ADP-
ribose-arginine bond.
ADP-ribosylarginine hydrolases from a variety of mammalian species
and tissues were isolated, and the coding regions for the hydrolases
were cloned and expressed. The availability of this new hydrolase cDNA
and expression system provides a novel molecular approach for studying
the role of ADP-ribosylation in cell function. The gene products may be
useful in treating or preventing a variety of bacterial diseases,
including cholera, that appear to be mediated via ADP-ribosylation.
Novel Anti-Mycobacterial Compositions And Their Use For The
Treatment Of Tuberculosis And Related Diseases
Barry, C.E., Yuan, Y. (NIAID)
Filed 18 Mar 94
Serial No. 08/210,519
This invention comprises a number of novel anti-mycobacterial
compositions, which offer to significantly improve the treatment of
mycobacterial infection such as tuberculosis. Mycobacterium is a genus
of bacteria encompassing a number of organisms, many of which are
highly pathogenic in humans. The most well known of these are M.
tuberculosis, which causes pulmonary tuberculosis, and M. leprae, which
causes leprosy. Tuberculosis is a major worldwide problem, especially
among HIV-infected and other immune-compromised individuals. Present
treatments for tuberculosis often have toxic side effects or have
limited utility because of the growing number of multi-drug resistant
strains of M. tuberculosis. These newly discovered anti-mycobacterial
compounds, which are analogs of thiatetracosanoate, have been shown
effective in the treatment of mycobacterial infections and are
relatively nontoxic. They may be given alone or in combination with
standard anti-mycobacterial drugs and are valuable as antiseptics as
well as therapeutics.
Dated October 21, 1994.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 94-26971 Filed 10-31-94; 8:45 am]
BILLING CODE 4140-01-P
